Kicking off the list is AbbVie Inc., which has managed to stave off generic challenge to its immunology product Humira (adalimumab) for some time in the US, but can no longer avoid the biosimilars set to debut in that market this year.
The TNF blocker first won US Food and Drug Administration approval in 2002 for rheumatoid arthritis before expanding to conditions...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?